Skip to main content
Clinical Trials/IRCT20150919024080N19
IRCT20150919024080N19
Recruiting
Phase 3

Comparison of the Effectiveness of Aromatherapy-Massage with Classic Massage in Chemotherapy-Induced Neuropathic Pain and Fatigue in Cancer Patients

Khoram-Abad University of Medical Sciences0 sites75 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Khoram-Abad University of Medical Sciences
Enrollment
75
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Khoram-Abad University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • The patient should be between 18 and 80 years old
  • Have at least one paraesthesia point (based on NRS)
  • More than 10,000 platelets per cubic millimeter of blood
  • No severe inflammatory lesions, itching or sores on the hands or feet
  • The patient must be in stage II or III cancer
  • Has received at least one session of chemotherapy and is scheduled to receive at least three more sessions within the next month
  • Existence of fatigue resistant to common treatments
  • If a specific cause for fatigue, such as anemia, insomnia, depression, or hypercalcemia, is identified, it should be treated first.
  • No history of peripheral neuropathy for any cause including diabetes mellitus, autoimmune disease, AIDS or previous chemotherapy
  • Patients with the infection are first treated with oral or intravenous antibiotics

Exclusion Criteria

  • Deep vein thrombosis
  • Perform Aromatherapy\-Massage for the past month
  • Dose reduction or discontinuation of medications
  • Allergy to lavender, chamomile and mint oils
  • Acute infections require oral or intravenous antibiotics or antiviral and antifungal drugs.
  • Drug therapy during the study to prevent or treat neuropathy
  • Existence of coagulation problems or taking anticoagulants
  • haemorrhage
  • Soft tissue infection
  • Oncological emergencies (such as Tumor Lysis Syndrome)

Outcomes

Primary Outcomes

Not specified

Similar Trials